0001493152-23-039093.txt : 20231102 0001493152-23-039093.hdr.sgml : 20231102 20231102105820 ACCESSION NUMBER: 0001493152-23-039093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231031 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Catelani Michael CENTRAL INDEX KEY: 0001689394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37492 FILM NUMBER: 231370665 MAIL ADDRESS: STREET 1: 12100 WILSHIRE BOULEVARD STREET 2: SUITE 1275 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER NAME: FORMER CONFORMED NAME: Catelini Michael DATE OF NAME CHANGE: 20161104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anixa Biosciences Inc CENTRAL INDEX KEY: 0000715446 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112622630 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 BUSINESS ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 BUSINESS PHONE: 408-708-9808 MAIL ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 FORMER COMPANY: FORMER CONFORMED NAME: ITUS Corp DATE OF NAME CHANGE: 20140902 FORMER COMPANY: FORMER CONFORMED NAME: COPYTELE INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml X0508 4 2023-10-31 0 0000715446 Anixa Biosciences Inc ANIX 0001689394 Catelani Michael C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE, CA 95118 0 1 0 0 President, COO & CFO 0 Common Stock 2023-10-31 4 A 0 1117 2.69 A 27772 D The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares. In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on October 31, 2023. /s/ Michael J. Catelani 2023-11-02